source
- FDA rejects Capricor's Duchenne cell therapy citing serious data integrity violationsThe Food and Drug Administration issued a second rejection of Capricor Therapeutics' cell therapy, deramiocel, aimed at treating Duchenne muscular dystrophy. The agency said the revised application…
- FDA clears Roche's Wilserdly pill for certain ER-positive, HER2-negative breast cancersThe U.S. Food and Drug Administration has approved Roche's new oral therapy Wilserdly for a specific group of breast cancer patients. The drug is indicated for adults with estrogen receptor‑positi…